Harbin Pharmaceutical Group Co

Harbin Pharmaceutical Group Co P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Harbin Pharmaceutical Group Co (600664.SS) as of Oct 28, 2026 is 31.14. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was 13.00 — a change of 139.58% (higher).

P/FCF

31.14

YoY

139.58%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Harbin Pharmaceutical Group Co is 2025 31.14 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Harbin Pharmaceutical Group Co was 2024 13.00 . It decreases by 139.58% higher compared to the previous year.

The Harbin Pharmaceutical Group Co P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
15.54 CNY
Jan 1, 2019
-27.76 CNY
Jan 1, 2020
-10.62 CNY
Jan 1, 2021
-37.60 CNY
Jan 1, 2022
16.89 CNY
Jan 1, 2023
10.42 CNY
Jan 1, 2024
13.00 CNY
Jan 1, 2025
31.14 CNY
The Harbin Pharmaceutical Group Co P/FCF history
YEARP/FCFYoY
31.14+139.58%
13.00+24.79%
10.42-38.31%
16.89-144.91%
-37.60+253.93%
-10.62-61.73%
-27.76-278.62%
15.54-91.84%
190.44+5,556.53%
3.37-48.73%
6.57-44.44%
11.82—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Harbin Pharmaceutical Group Co Stock analysis

What does Harbin Pharmaceutical Group Co do? Harbin Pharmaceutical Group Co., Ltd. generates revenue by engaging in the research, development, manufacture, wholesale, and retail of pharmaceutical products. The firm focuses on innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals. These activities support its main business sectors, which include antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The company produces a wide range of items, including calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, and Xingaizhonggai high calcium tablets. The business is structured around these diverse product lines, serving the needs of the pharmaceutical commerce sector and consumers requiring specific medical treatments. By covering the entire value chain from research and development to retail, the company monetizes its expertise in high-tech fields. The products listed, such as Shuanghuanglian oral solution and amoxicillin capsules, represent the tangible outputs of its manufacturing and wholesale operations, which are central to its financial model. Harbin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Harbin Pharmaceutical Group Co stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Harbin Pharmaceutical Group Co is 31.14 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Harbin Pharmaceutical Group Co changed from 13.00 to 31.14, representing a 139.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Harbin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Harbin Pharmaceutical Group Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Harbin Pharmaceutical Group Co

All Key Metrics — Harbin Pharmaceutical Group Co